| T vs. C | regorafenib | BSC | atezolizumab alone | durvalumab plus tremelimumab | atezolizumab plus cometinib |
| regorafenib | --- | NA | NA | NA | NA |
| BSC | NA | --- | NA | NA | NA |
| atezolizumab alone | NA | NA | --- | NA | NA |
| durvalumab plus tremelimumab | NA | NA | NA | --- | NA |
| atezolizumab plus cometinib | NA | NA | NA | NA | --- |
pathologies: 138
- treatments: 696
result logic
